University of Arkansas for Medical Science-MIRT
Welcome,         Profile    Billing    Logout  
 15 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Barlogie, Bart
NCT00999414: UARK 2009-32 Compassionate Use Study of Carfilzomib

No Longer Available
N/A
US
Carfilzomib
University of Arkansas, Onyx Therapeutics, Inc.
Multiple Myeloma
04/15
04/15
Zangari, Maurizio
TT4B, NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

Active, not recruiting
3
382
US
M-VTD-PACE, Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide, TT3-LITE Regimen (L-TT3), Velcade (bortezomib)
University of Arkansas, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
09/25
09/26
NCT00871013: Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Active, not recruiting
2
160
US
Melphalan, Alkeran, Velcade, Bortezomib, PS-341, Thalidomide, Thalomid, Dexamethasone, Decadron, Cisplatin, Platinol, CDDP, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Vepesid, VP-16
University of Arkansas
Myeloma
12/25
12/25
Rhee, Frits van
NCT03004287: 2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting
2
50
US
Carfilzomib, Kyprolis, Thalidomide, Thalomid, Dexamethasone, Baycadron, Daratumumab, Darzalex, Cisplatin, Platinol, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, ASCT, Lenalidomide, Revlimid, Bortezomib, Velcade
University of Arkansas, Janssen, LP
Multiple Myeloma
10/25
10/26
NCT03933904: Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

Active, not recruiting
2
24
US
Sirolimus, Rapamune, Rapamycin
University of Pennsylvania
Castleman Disease, Castleman's Disease, Multicentric
06/24
06/25
NCT00869232: UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Active, not recruiting
2
90
US
Velcade, PS-341, Melphalan, Alkeran, Thalidomide, Thalomid, Dexamethasone, Decadron, Cisplatin, Platinol, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Vp-16, Vepesid
University of Arkansas
Multiple Myeloma
10/25
10/26
NCT04396496: Treatment of POEMS Syndrome With Daratumumab

Completed
2
2
US
Daratumumab Injection, Darzalex
University of Arkansas, Janssen Scientific Affairs, LLC
POEMS Syndrome
08/23
10/23
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
Muzaffar, Jameel
NCT03811015: Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Suspended
3
636
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
01/27
01/27
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
CAPS, NCT03781986: APG-115 in Salivary Gland Cancer Trial

Active, not recruiting
1/2
41
US
APG-115, Carboplatin
University of Michigan Rogel Cancer Center, Ascentage Pharma Group Inc.
Malignant Salivary Gland Cancer, Salivary Gland Cancer
06/25
12/25
KEYNOTE-E28, NCT04429542: Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Recruiting
1
292
Canada, US, RoW
BCA101, Ficerafusp alfa, Pembrolizumab
Bicara Therapeutics, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
12/26
06/27
NCT05083416: Effect of Prolonged Nightly Fasting on Immunotherapy Outcomes in HNSCC - Role of Gut Microbiome

Completed
N/A
29
US
Prolonged Nightly Fasting, Intermittent Fasting, Regular Eating pattern
H. Lee Moffitt Cancer Center and Research Institute, American Cancer Society, Inc.
Head and Neck Cancer
03/23
04/24
NCT06603155: Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC)

Recruiting
N/A
55
US
Time restricted eating (TRE)
Duke University
Metastatic Head-and-neck Squamous-cell Carcinoma
06/26
06/26
Apewokin, Senu
NCT03734393: HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients

Active, not recruiting
N/A
80
US
HIVD+/R+
Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID)
Hiv
04/25
06/25
Atrash, Shebli
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT04756401: Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Active, not recruiting
2
52
US
Carfilzomib, Kyprolis, PR-171, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Quality-of-Life Assessment, Quality of Life Assessment, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
09/24
12/27
NCT03773107: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Completed
1/2
12
US
Carfilzomib, Kyprolis, Ruxolitinib, Jakafi, Dexamethasone
Wake Forest University Health Sciences, Incyte Corporation, Multiple Myeloma Research Consortium, Amgen
Multiple Myeloma
11/22
02/24
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
NCT04822337: Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Recruiting
1/2
70
US
Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
Wake Forest University Health Sciences, Amgen, GlaxoSmithKline
Multiple Myeloma
04/29
11/32
Matin, Aasiya
NCT04479267: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Recruiting
2
49
US
Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione, 53-03-2, Adasone, Cortancyl, Dacortin, , Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, 1,2-Dehydrohydrocortisone, 50-24-8, 9120, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Methylprednisolone, (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione, 6Alpha-Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Rituximab, 174722-31-7, 687451, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, POLATUZUMAB VEDOTIN, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Cyclophosphamide, 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Doxorubicin Hydrochloride, 14-Hydroxydaunorubicin Hydrochloride, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma, High-grade B-cell Lymphoma
11/25
11/26
ALLOHA, NCT05473910: A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Recruiting
1
63
US
SOC + TSC-100, SOC + TSC-101, Control
TScan Therapeutics, Inc.
AML, Myelodysplastic Syndromes, ALL, Adult
12/25
06/26
Bakhous, Aziz
No trials found
Grazziutti, Monica
No trials found
Petty, Nathan
No trials found

Download Options